Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-01-09 (mondaq.com)
Are Reference Product Sponsors Asserting More Patents In BPCIA Litigation? - Patent - United States
On October 24, 2014, Amgen initiated the first litigation under the Biologics Price Competition and Innovation Act ("BPCIA"), asserting infringement of two patents.
Read more
2024-12-31 (bigmoleculewatch.com)
Are Reference Product Sponsors Asserting More Patents in BPCIA Litigation? -
On October 24, 2014, Amgen initiated the first litigation under the Biologics Price Competition and Innovation Act (“BPCIA”), asserting infringement of two patents.
Read more
2023-10-05 (masslawyersweekly.com)
Landlord and tenant – Contribution – Indemnification
Where a plaintiff that subleased a commercial building from the defendant tenant filed a complaint alleging that the phased redevelopment of Kendall Square has impacted its use of the premises, the defendant’ s motion for leave to file a third-party complaint against the landlord should be denied
Read more
2023-04-04 (masslawyersweekly.com)
Securities - Fraud - Knowingly
Where a securities fraud complaint has been filed over the failed commercial rollout of an innovative treatment for Alzheimer's disease, the complaint must be dismissed because (1) none of the defendants' 25 allegedly false and misleading statements are actionable under the Private Securities
Read more
2022-02-06 (jdsupra.com)
Biosimilars 2022 Year in Review | JD Supra
2022 heralded the next chapter for biosimilars in the United States, including U.S. Food and Drug Administration approval of biosimilars in new...
Read more
(tijd.be)
Testaankoop files a complaint against 'extortionate price' muscle disease medicine |
The consumer organization believes that the pharmaceutical giant Biogen is abusing its monopoly position by charging an 'extortionate price' for Spinraza.
Read more
(jdsupra.com)
Genentech, Roche, and Biogen Sue Dr. Reddy’s and Fresenius for a Proposed Biosimilar of Rituxan in District of New Jersey | JD Supra
Genentech, Roche, and Biogen filed a Complaint on November 17 against Dr. Reddy’s Laboratories (“DRL”) and Fresenius in the U.S. District Court...
Read more